Compare Amplify Cybersecurity ETF (HACK) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplify Cybersecurity ETF vs Twist Bioscience Corp — how do they compare? Amplify Cybersecurity ETF trades at $123.68 (market cap $3.55B), while Twist Bioscience Corp trades at $156.75 (market cap $10.32B). The key difference: Twist Bioscience Corp is far larger — about 2.9× Amplify Cybersecurity ETF's market cap, and Amplify Cybersecurity ETF is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Amplify Cybersecurity ETF for 30 Days and Twist Bioscience Corp for 27 Days on average.
| HACK | TWST | |
|---|---|---|
Market Cap | $3.55B | $10.32B |
Volume | 233,961 | 5,894,998 |
Sector | Sector/Thematic | Health |
52-Week High | $127.66 | $205.00 |
52-Week Low | $70.69 | $25.45 |
Typical Hold Time | 30 Days | 27 Days |
Enterprise Value | — | $10.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HACK trades at $125.81, down 1.45% today but near its 52-week high, with a strong technical outlook showing bullish moving averages and key support at $124. Recent news highlights the ETF's momentum, driven by AI safety concerns and cybersecurity demand, with the fund up 84.96% from its 52-week low. Financial ratios are not disclosed for this ETF, but sector growth remains a tailwind.
The outlook for HACK is positive, supported by rising cybersecurity spending and AI-driven threats, though risks include increased short interest and sector volatility. Analyst sentiment is bullish, with the ETF positioned to benefit from ongoing digital security trends, but investors should monitor competitive and macroeconomic pressures.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amplify Cybersecurity ETF
HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
